Rapid Novor
Latest round
- Series A
Last raised
- Jul 2020
Total raised
- $5M
Investors
- 1
About Rapid Novor
Rapid Novor, Inc. is a biotechnology company established in 2015, specializing in antibody discovery and characterization through innovative sequencing technologies.Founded in 2015 and headquartered in Kitchener, Ontario, Canada, Rapid Novor, Inc. focuses on the sequencing of antibodies without the need for hybridoma or DNA information. The company has not undergone any significant pivots or changes in operations since its inception.Rapid Novor specializes in antibody characterization and discovery utilizing patented technology that enables the sequencing of antibodies from small protein samples without the need for hybridoma or DNA information. Their core offerings include monoclonal and polyclonal antibody sequencing, epitope mapping through mass spectrometry, and surface plasmon resonance for the label-free evaluation of antibody-antigen binding. These services empower biotech and pharmaceutical companies to achieve life science breakthroughs by providing insights into immune responses, optimizing antibody development, and facilitating the identification of high-quality therapeutic molecules. Rapid Novor serves over 650 clients across pharmaceuticals, biotechnology, and diagnostics, with a focus on markets in North America, Europe, and select regions in Asia.Rapid Novor operates primarily on a business-to-business (B2B) model, providing antibody sequencing and discovery services to clients in the pharmaceutical and biotech sectors. The firm engages in contract-based agreements where clients utilize its advanced technologies for specific research and development projects. Transactions are structured as fee-for-service engagements, with pricing plans tailored to project scopes. The company plans to develop new antibody characterization products and explore additional applications of their patented technologies. Furthermore, Rapid Novor is targeting expansion into new geographic markets across Europe and Asia by 2023, enhancing their service reach and client base.
Who invested in Rapid Novor
1 investor across 1 round
See all investors in Rapid Novor
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 28, 2020
Amount
$5M
Investors
Questions about Rapid Novor
Who invested in Rapid Novor?
Rapid Novor has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rapid Novor raised?
Rapid Novor has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Rapid Novor last raise money?
Rapid Novor's most recent round on record is a Series A, in Jul 2020.
What does Rapid Novor do?
Rapid Novor is a biotechnology company.
Where is Rapid Novor headquartered?
Rapid Novor is headquartered in Kitchener, Canada.
Which VCs invest in companies like Rapid Novor?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rapid Novor's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Rapid Novor? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.